PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients |
|
|
| Active, not recruiting | 2 | 140 | Europe | cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2 | Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories | Primary Central Nervous System Lymphoma | 05/16 | 05/26 | | |